Raymond James analyst John Ransom upgraded Alignment Healthcare to Outperform from Market Perform with a $9 price target. While the stock has been pressured year-to-date due to policy overhangs and concerns over recovering utilization, Alignment Healthcare now offers a favorable risk/reward profile given the company’s current valuation, MLR expectations for Q1 of 90.9% that appear conservative, and the clearing of recent policy overhangs, the analyst tells investors in a research note.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on ALHC:
- Alignment Healthcare upgraded to Outperform at Raymond James
- Alignment Healthcare to Participate in the BofA Securities 2023 Health Care Conference
- Alignment Health CEO to Share Insights on Digital Health, Whole-Person Care at 2023 Milken Institute Global Conference
- Alignment Healthcare to Announce First Quarter 2023 Financial Results and Host Conference Call Thursday, May 4, 2023
- TD Cowen healthcare analyst to hold analyst/industry conference call
